These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29733695)

  • 1. Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.
    Gaur S; Harmon S; Rosenblum L; Greer MD; Mehralivand S; Coskun M; Merino MJ; Wood BJ; Shih JH; Pinto PA; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2018 Jul; 211(1):W33-W41. PubMed ID: 29733695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI.
    Benndorf M; Hahn F; Krönig M; Jilg CA; Krauss T; Langer M; Dovi-Akué P
    Eur J Radiol; 2017 Aug; 93():9-15. PubMed ID: 28668436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3 + 4 and 4 + 3 prostate cancer.
    Alessandrino F; Taghipour M; Hassanzadeh E; Ziaei A; Vangel M; Fedorov A; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Jan; 44(1):279-285. PubMed ID: 30066169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
    Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
    J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
    Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
    Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
    Gaur S; Harmon S; Mehralivand S; Bednarova S; Calio BP; Sugano D; Sidana A; Merino MJ; Pinto PA; Wood BJ; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2018 Nov; 48(5):1326-1335. PubMed ID: 29603833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer.
    Park SY; Shin SJ; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ; Oh YT
    Eur Radiol; 2017 Jul; 27(7):2776-2783. PubMed ID: 27957637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.
    Nougaret S; Robertson N; Golia Pernicka J; Molinari N; Hötker AM; Ehdaie B; Sala E; Hricak H; Vargas HA
    Abdom Radiol (NY); 2017 Jul; 42(7):1968-1974. PubMed ID: 28258355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
    Tosun M; Uslu H
    Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Inclusion of Apparent Diffusion Coefficients in Multiparametric Prostate MRI Structured Reports: Discrimination of Clinically Insignificant and Significant Cancers.
    Costa DN; Xi Y; Aziz M; Passoni N; Shakir N; Goldberg K; Francis F; Roehrborn CG; Leon AD; Pedrosa I
    AJR Am J Roentgenol; 2019 Jan; 212(1):109-116. PubMed ID: 30383404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra- and interreader reproducibility of PI-RADSv2: A multireader study.
    Smith CP; Harmon SA; Barrett T; Bittencourt LK; Law YM; Shebel H; An JY; Czarniecki M; Mehralivand S; Coskun M; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2019 Jun; 49(6):1694-1703. PubMed ID: 30575184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
    Felker ER; Raman SS; Margolis DJ; Lu DSK; Shaheen N; Natarajan S; Sharma D; Huang J; Dorey F; Marks LS
    AJR Am J Roentgenol; 2017 Dec; 209(6):1272-1277. PubMed ID: 28858541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral zone lesions of intermediary risk in multiparametric prostate MRI: Frequency and validation of the PI-RADSv2 risk stratification algorithm based on focal contrast enhancement.
    Benndorf M; Waibel L; Krönig M; Jilg CA; Langer M; Krauss T
    Eur J Radiol; 2018 Feb; 99():62-67. PubMed ID: 29362152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the addition of quantitative apparent diffusion coefficient data on the diagnostic performance of the PI-RADS v2 scoring system to detect clinically significant prostate cancer.
    Moraes MO; Roman DHH; Copetti J; de S Santos F; Agra A; Noronha JAP; Carvalhal G; Neto EJD; Zanon M; Baldisserotto M; Hochhegger B
    World J Urol; 2020 Apr; 38(4):981-991. PubMed ID: 31175458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
    Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
    In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
    Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
    Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
    De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
    Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).
    Gaur S; Harmon S; Gupta RT; Margolis DJ; Lay N; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
    Acad Radiol; 2019 Jan; 26(1):5-14. PubMed ID: 29705281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All over the map: An interobserver agreement study of tumor location based on the PI-RADSv2 sector map.
    Greer MD; Shih JH; Barrett T; Bednarova S; Kabakus I; Law YM; Shebel H; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2018 Aug; 48(2):482-490. PubMed ID: 29341356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.